CACaption Management, LLC
Institutional investor · Portfolio as of Q4 2019
Top Holdings801 positions
MEDICINES CO | 818,300 | $69.5M | 2.3% | — | — | — | Decreased — |
CHIPOTLE MEXICAN GRILL INC | 59,900 | $50.1M | 1.7% | — | — | — | New — |
INTRA-CELLULAR THERAPIES INC | 1.4M | $47.8M | 1.6% | — | — | — | Increased — |
MEDICINES CO | 554,500 | $47.1M | 1.6% | — | — | — | Decreased — |
IQVIA Holdings Inc. | 300,000 | $46.4M | 1.6% | — | — | — | New — |
ZENDESK INC | 500,000 | $38.3M | 1.3% | — | — | — | New — |
DEXCOM INC | 170,000 | $37.2M | 1.2% | — | — | — | New — |
Biohaven Ltd. | 618,300 | $33.7M | 1.1% | — | — | — | Increased — |
EXACT SCIENCES CORP | 345,300 | $31.9M | 1.1% | — | — | — | Increased — |
BIOMARIN PHARMACEUTICAL INC | 341,500 | $28.9M | 1.0% | — | — | — | New — |
UNIQURE NV | 397,304 | $28.5M | 1.0% | $70.63 | +1.46% | 3 qtrssince 2019-Q2 | Increased 65 |
MEDICINES CO | 333,600 | $28.3M | 1.0% | — | — | 4 qtrssince 2019-Q1 | Increased 46 |
TRANSDIGM GROUP INC | 49,400 | $27.7M | 0.9% | — | — | — | New — |
INTRA-CELLULAR THERAPIES INC | 804,300 | $27.6M | 0.9% | — | — | — | Increased — |
MARATHON PETE CORP | 422,500 | $25.5M | 0.9% | — | — | — | Increased — |
EXACT SCIENCES CORP | 271,500 | $25.1M | 0.8% | — | — | — | Increased — |
MIRATI THERAPEUTICS INC | 194,300 | $25M | 0.8% | — | — | — | Increased — |
PELOTON INTERACTIVE INC | 847,500 | $24.1M | 0.8% | — | — | — | New — |
ILLUMINA INC | 70,000 | $23.2M | 0.8% | — | — | — | New — |
WW INTL INC | 552,600 | $21.1M | 0.7% | — | — | — | Increased — |
Caption Management, LLC manages $3B across 801 positions as of Q4 2019. Top holdings: MDCO puts (2.3%), CMG puts (1.7%), ITCI puts (1.6%). Fund DNA: Momentum Trader. HoldingsIntel Score: 1/5.0.
Active quarter - 154 new positions, 121 exits, 59 increased. Top move: QURE (INCREASED, conviction 65). Portfolio: $3.0B across 801 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR